Company intelligence / Profile preview

Aanastra Inc

Los Angeles, California, United Statesaanastra.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Aanastra has shown remarkable antitumor effects in animal models of various cancers with P53, KRAS, or BRCA1 mutations. The company has also demonstrated efficacy in animal models of hemophilia A to normalize Factor VIII levels and in cholesterol lowering applications by targeting PCSK9[1][2].

Therapeutic areas
OncologyCardiovascularGastroenterologyHematology
Modalities
RNA therapeuticsmRNAGene editingCRISPR/Cas9Therapeutic vaccinemRNA vaccine
Industry
Biotech
02

Drug pipeline

12 assets

ADGN-F8

Preclinical

11 more assets in the full pipeline.

03

Partnerships

Divincell SAS (sister company)

Beyond the preview

Go deeper on Aanastra Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aanastra Inc.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call